| Literature DB >> 35348667 |
Bart Maesen1,2, Sander Verheule2,3, Stef Zeemering2,3, Mark La Meir4, Jan Nijs4, Stijn Lumeij3, Dennis H Lau3, Mathieu Granier3, Harry Jgm Crijns2,5, Jos G Maessen1,2, Stefan Dhein6, Ulrich Schotten2,3.
Abstract
AIMS: Although in persistent atrial fibrillation (AF) a complex AF substrate characterized by a high incidence of conduction block has been reported, relatively little is known about AF complexity in paroxysmal AF (pAF). Also, the relative contribution of various aspects of structural alterations to conduction disturbances is not clear. In particular, the contribution of endomysial fibrosis to conduction disturbances during progression of AF has not been studied yet. METHODS ANDEntities:
Keywords: AF complexity; AF substrate; Atrial fibrillation; Endomysial fibrosis; Epicardial mapping; Fibrosis
Mesh:
Substances:
Year: 2022 PMID: 35348667 PMCID: PMC9282911 DOI: 10.1093/europace/euac026
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.486
Patient characteristics
| Acute AF ( | Paroxysmal AF ( | Persistent AF ( |
| |
|---|---|---|---|---|
| Age (years) | 61.6 ± 9.3 | 68.6 ± 4.0[ | 69.1 ± 5.8[ | 0.03 |
| Male sex (%) | 72.7 | 75.0 | 55.6 | 0.63 |
| Clinical characteristics | ||||
| Hypertension (%) | 63.6 | 66.7 | 77.8 | 0.80 |
| Diabetes (%) | 18.2 | 8.3 | 44.4 | 0.14 |
| Peripheral arterial disease (%) | 27.3 | 16.7 | 22.2 | 0.84 |
| Myocardial infarction (%) | 36.4 | 25.0 | 11.1 | 0.46 |
| GFR < 60 mL/min (%) | 0 | 25.0 | 22.2 | 0.22 |
| BMI (kg/m2) | 26.9 ± 2.5 | 27.5 ± 5.1 | 26.9 ± 3.1 | 0.35 |
| NYHA class | 2 (2–3) | 2 (1–2.75) | 2 (2–3) | 0.63 |
| CHA2DS2-Vasc | 3 (3–4) | 3 (2–3.75) | 3 (3–6)[ | 0.09 |
| Surgery | 0.40 | |||
| CABG+MVS | 2 | – | – | |
| CABG | 7 | 8 | 4 | |
| MVS | 2 | 1 | 2 | |
| AVS | – | 2 | 2 | |
| Lone AF | – | 1 | 1 | |
| Echocardiography | ||||
| LA diameter (mm) | 43.0 ± 7.1 | 43.1 ± 7.9 | 53.1 ± 6.1*,§ | 0.005 |
| LA volume (cm3) | 87.4 ± 35.0 | 79.2 ± 26.1 | 151.0 ± 55.3*,§ | <0.001 |
| RA volume (cm3) | 47.9 ± 17.0 | 50.9 ± 25.7 | 102.8 ± 32.3*,§ | <0.001 |
| LVEF (%) | 55.5 ± 14.1 | 64.0 ± 8.7 | 61.4 ± 6.4 | 0.18 |
| Drugs | ||||
| Betablocker (%) | 72.7 | 83.3 | 77.8 | 0.84 |
| Digoxin (%) | – | 0 | 33.3[ | 0.01 |
| Amiodarone/sotalol (%) | – | 58.3 | 11.1[ | 0.001 |
| CCB (%) | 18.2 | 33.3 | 33.3 | 0.69 |
| AF duration (years) | – | 7.0 ± 6.9 | 9.6 ± 6.6[ | 0.004 |
AF, atrial fibrillation; AVS, aortic valve surgery; BMI, body mass index; CABG, coronary artery bypass grafting; CCB, Calcium channel blocker; GFR, glomerular filtration rate; LA(A), left atrial (appendage); LVEDD, left ventricular end diastolic diameter; MVS, mitral valve surgery; NYHA, New York Heart Association; RA, right atrial.
P < 0.05 vs. acute AF.
P < 0.05 vs. paroxysmal AF.
Parameters of the AF conduction pattern
| Acute AF ( | Paroxysmal AF ( | Persistent AF ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| RA | pLA | LAA | RA | pLA | LAA | RA | pLA | LAA | |
| Waves/cycle | 5.7 ± 2.2 | 9.6 ± 3.6[ | 2.8 ± 1.4 | 6.5 ± 2.7 | 8.5 ± 3.8 | 3.2 ± 0.7 | 11.2 ± 3.9*,§ | 17.9 ± 3.9*,§,‡ | 3.7 ± 1.1 |
| BT/cycle | 1.9 ± 0.9 | 4.2 ± 2.3[ | 0.6 ± 0.6 | 2.4 ± 1.8 | 3.4 ± 2.3 | 0.7 ± 0.4 | 4.8 ± 2.3*,§ | 9.0 ± 2.6*,§,‡ | 0.9 ± 0.5 |
| Wave size (mm2) | 120.1 ± 75.9 | 65.6 ± 27.4[ | 61.1 ± 30.5 | 98.8 ± 43.1 | 66.1 ± 23.8[ | 46.4 ± 12.7 | 53.7 ± 20.0*,§ | 28.9 ± 8.4*,§,‡ | 34.0 ± 13.1*,§ |
| FI | 1.0 ± 0.4 | 2.5 ± 0.7[ | 1.6 ± 1.0[ | 1.3 ± 0.5 | 2.3 ± 1.1[ | 2.9 ± 1.7*,‡ | 1.9 ± 0.8*,§ | 4.5 ± 1.1*,§,‡ | 4.0 ± 1.5*,‡ |
AF, atrial fibrillation; BT, breakthrough; FI, fractionation index; RA, right atrium; pLA, posterior left atrium; LAA, left atrial appendage.
P < 0.05 vs. acute AF.
P < 0.05 vs. paroxysmal AF.
P < 0.05 vs. RA.
P < 0.05 vs. PLA (only for FI).